Skip to content

Gastrointestinal Tolerance And Gut Health Outcomes With Low-Viscosity Soluble Fiber (Resistant Maltodextrin) in ICU Patients A Multicenter Prospective Randomized Study

Clinical Impact Of Low-Viscosity Soluble Fiber (Resistant Maltodextrin) Supplementation In ICU Patients: A Multicenter Randomised Double Arm Open Label Prospective Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106476
Enrollment
500
Registered
2026-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E63- Other nutritional deficiencies Health Condition 2: E638- Other specified nutritional deficiencies

Interventions

Intervention1: Soluble Fiber Resistant Maltodextrin: 30 gm fiber / day Study Period Period of ICU Stay Minimum 3 Days Maximum 5 Days and With A Followup of 7 Days Control Intervention1: No Fiber Suppl

Sponsors

Hexagon Nutrition Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients more than 18 years of age Hemodynamically stable defined as no escalating high-dose vasopressors in last 24 hours Patients who are fed only on Scientific formulas Acutely admitted to the medical or surgical ICU Admitted to ICU and expected to require enteral tube feeding via for nasogastric tube more than or equal to 72 hours Informed Consent from the patient surrogate

Exclusion criteria

Exclusion criteria: Age below 18 years of age Contraindication to EN or PN Post organ Transplant Patients who are on Pharmacotherapeutic agents Laxatives Purgatives and Prokinetic agents Pregnancy and Lactating mothers Preexisting Inflammatory bowel disease Short bowel syndrome with high output fistula Bowel obstruction Ischemia Active GI bleed Infective diarrhea Chronic diarrhea GI motility GRV more than 500 ml despite prokinetics ileus chronic constipation Major GI surgery with contraindications to enteral fiber surgeon discretion Known allergy or intolerance to the enteral formulas or on blenderized feeds or on exclusive PN Limited life expectancy Participation in any clinical trial in the last 3 months

Design outcomes

Primary

MeasureTime frame
To evaluate the effect of Resistant Maltodextrin soluble fiber specifically PentaSure Fiber as a prebiotic in ICU patients as an prophylactic treatment with the aim of minimizing GI disturbances and improving gut healthTimepoint: Within 24 to 48 hrs of Enteral Feed Day 1 Day 2 Day 3 Day 4 Day 5 Followup

Secondary

MeasureTime frame
To evaluate the effectiveness of soluble fiber in regulating blood sugar levels among critically ill patients To monitor enteral nutrition tolerance and nutritional adequacy calories protein delivered vs prescribed To assess the need for laxatives and anti diarrheal medicationsTimepoint: within 24 to 48 hrs of Enteral Feed Day 1 Day 2 Day 3 Day 4 Day 5 Followup

Countries

India

Contacts

Public ContactDr Sunitha Premalatha

Hexagon Nutrition Ltd

jyotinunse@gmail.com8087079336

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026